Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

237 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study.
Solomon BJ, Bauer TM, Mok TSK, Liu G, Mazieres J, de Marinis F, Goto Y, Kim DW, Wu YL, Jassem J, López FL, Soo RA, Shaw AT, Polli A, Messina R, Iadeluca L, Toffalorio F, Felip E. Solomon BJ, et al. Among authors: messina r. Lancet Respir Med. 2023 Apr;11(4):354-366. doi: 10.1016/S2213-2600(22)00437-4. Epub 2022 Dec 16. Lancet Respir Med. 2023. PMID: 36535300 Clinical Trial.
Plain language summary of the updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancer.
Solomon BJ, Bauer TM, K Mok TS, Liu G, Mazieres J, Marinis F, Goto Y, Kim DW, Wu YL, Jassem J, López FL, Soo RA, Shaw AT, Polli A, Messina R, Iadeluca L, Toffalorio F, Felip E. Solomon BJ, et al. Among authors: messina r. Future Oncol. 2023 May;19(14):961-973. doi: 10.2217/fon-2022-1289. Epub 2023 Jun 12. Future Oncol. 2023. PMID: 37306090 Free article. Review.
Factors Associated With Developing Neurocognitive Adverse Events in Patients Receiving Lorlatinib After Progression on Other Targeted Therapies.
Dagogo-Jack I, Abbattista A, Murphy JF, Krulewicz S, Do A, Peterson J, Lin JJ, Gainor JF, Messina R, Krueger EA, Thurm H, Yeap BY. Dagogo-Jack I, et al. Among authors: messina r. J Thorac Oncol. 2023 Jan;18(1):67-78. doi: 10.1016/j.jtho.2022.09.219. Epub 2022 Sep 29. J Thorac Oncol. 2023. PMID: 36184067 Free article.
Women in leadership positions in Italian neurosurgery.
Murthy S, Silva Correia IF, Messina R. Murthy S, et al. Among authors: messina r. Brain Spine. 2024 Jan 26;4:102752. doi: 10.1016/j.bas.2024.102752. eCollection 2024. Brain Spine. 2024. PMID: 38510639 Free PMC article. No abstract available.
A multi-state analysis of disease trajectories and mental health transitions in patients with type 2 diabetes: A population-based retrospective cohort study utilizing health administrative data.
Lenzi J, Messina R, Rosa S, Iommi M, Rucci P, Pia Fantini M, Di Bartolo P. Lenzi J, et al. Among authors: messina r. Diabetes Res Clin Pract. 2024 Mar;209:111561. doi: 10.1016/j.diabres.2024.111561. Epub 2024 Feb 5. Diabetes Res Clin Pract. 2024. PMID: 38325659 Free article.
Health equity, care access and quality in headache - part 2.
Raffaelli B, Rubio-Beltrán E, Cho SJ, De Icco R, Labastida-Ramirez A, Onan D, Ornello R, Ruscheweyh R, Waliszewska-Prosół M, Messina R, Puledda F. Raffaelli B, et al. Among authors: messina r. J Headache Pain. 2023 Dec 13;24(1):167. doi: 10.1186/s10194-023-01699-7. J Headache Pain. 2023. PMID: 38087219 Free PMC article. Review.
237 results